The ICGEA report acknowledges the transformative role played by various actors, including hospitals, research centers, the pharmaceutical industry, specialized clinics, and patient organizations. These entities are driving a new era in cancer prevention and comprehensive treatment, marked by innovation, precision medicine, and advanced therapies.
“"The progress in oncology no longer depends on a single actor. Real progress occurs when the pharmaceutical industry, reference hospitals, research centers, and a public-private health system capable of integrating innovation efficiently and equitably converge."
Among the research and hospital centers, the report highlights the Comprehensive Cancer Center at Hospital Universitario Fundación Jiménez Díaz, directed by Dr. Jesús García-Foncillas, as a model for translating precision oncology into clinical practice. Also mentioned are the National Cancer Research Center (CNIO), for pancreatic cancer advances by Mariano Barbacid's team, and the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, led by Dr. Josep Tabernero.
Regarding the pharmaceutical industry, the ICGEA emphasizes the role of Novartis, for its commitment to precision medicine; AstraZeneca, which uses Spain as a key country from its Barcelona hub; and Gilead Sciences, for its leadership in CAR-T cell therapies and options for metastatic breast cancer.
The analysis also values high specialization, noting the Centro de Protonterapia Fundación Jiménez Díaz and the Clínica Universidad de Navarra. Finally, the essential role of patient organizations in humanizing the oncological approach is recognized, highlighting the work of the Spanish Group of Cancer Patients (GEPAC) and the Spanish Association Against Cancer (AECC).
